Assessing in vivo mutation frequencies and creating a high-resolution genome-wide map of fitness costs of Hepatitis C virus.
Journal
PLoS genetics
ISSN: 1553-7404
Titre abrégé: PLoS Genet
Pays: United States
ID NLM: 101239074
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
received:
20
12
2021
accepted:
30
03
2022
revised:
17
05
2022
pubmed:
3
5
2022
medline:
20
5
2022
entrez:
2
5
2022
Statut:
epublish
Résumé
Like many viruses, Hepatitis C Virus (HCV) has a high mutation rate, which helps the virus adapt quickly, but mutations come with fitness costs. Fitness costs can be studied by different approaches, such as experimental or frequency-based approaches. The frequency-based approach is particularly useful to estimate in vivo fitness costs, but this approach works best with deep sequencing data from many hosts are. In this study, we applied the frequency-based approach to a large dataset of 195 patients and estimated the fitness costs of mutations at 7957 sites along the HCV genome. We used beta regression and random forest models to better understand how different factors influenced fitness costs. Our results revealed that costs of nonsynonymous mutations were three times higher than those of synonymous mutations, and mutations at nucleotides A or T had higher costs than those at C or G. Genome location had a modest effect, with lower costs for mutations in HVR1 and higher costs for mutations in Core and NS5B. Resistance mutations were, on average, costlier than other mutations. Our results show that in vivo fitness costs of mutations can be site and virus specific, reinforcing the utility of constructing in vivo fitness cost maps of viral genomes.
Identifiants
pubmed: 35500034
doi: 10.1371/journal.pgen.1010179
pii: PGENETICS-D-21-01670
pmc: PMC9113599
doi:
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1010179Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
PLoS Genet. 2019 Oct 17;15(10):e1008271
pubmed: 31622336
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Drug Resist Updat. 2018 Mar;37:17-39
pubmed: 29525636
J Infect Dis. 2015 Apr 15;211(8):1288-95
pubmed: 25389307
Nat Microbiol. 2016 Apr 18;1(7):16045
pubmed: 27572964
Virology. 2015 May;479-480:46-51
pubmed: 25824477
Science. 1999 Dec 3;286(5446):1921-5
pubmed: 10583948
Gut Liver. 2016 Nov 15;10(6):890-895
pubmed: 27784846
J Hepatol. 2016 Feb;64(2):486-504
pubmed: 26409317
J Virol. 2001 Jan;75(1):251-9
pubmed: 11119595
JAMA. 2011 Apr 6;305(13):1327-35
pubmed: 21467286
BMC Evol Biol. 2011 May 19;11:131
pubmed: 21595904
J Virol. 2016 Jan 06;90(6):3112-22
pubmed: 26739044
J Virol. 2009 Jun;83(11):5760-4
pubmed: 19321623
PLoS Pathog. 2012;8(8):e1002881
pubmed: 22927817
Next Gener Seq Appl. 2014;1:
pubmed: 25699289
Antiviral Res. 2014 Aug;108:181-91
pubmed: 24911972
Genetics. 1931 Mar;16(2):97-159
pubmed: 17246615
Evol Ecol. 2020;34(3):339-359
pubmed: 32508375
Microb Comp Genomics. 2000;5(3):129-51
pubmed: 11252351
Viruses. 2021 Mar 19;13(3):
pubmed: 33808782
Nature. 2014 Mar 6;507(7490):57-61
pubmed: 24572367
Viruses. 2018 Nov 01;10(11):
pubmed: 30388745
Virus Res. 2016 Sep 2;223:140-6
pubmed: 27449600
Nature. 2014 Jan 30;505(7485):686-90
pubmed: 24284629
PLoS One. 2013 Sep 23;8(9):e74109
pubmed: 24086312
World J Hepatol. 2015 Apr 28;7(6):831-45
pubmed: 25937861
J Virol. 2015 Aug;89(16):8540-55
pubmed: 26041299
Cell Host Microbe. 2017 Oct 11;22(4):437-441
pubmed: 29024640
Proc Natl Acad Sci U S A. 2015 Mar 24;112(12):3692-7
pubmed: 25775547
Int J Epidemiol. 2010 Oct;39(5):1162-9
pubmed: 19786463
PLoS Genet. 2018 Jun 28;14(6):e1007420
pubmed: 29953449
PLoS One. 2008;3(10):e3376
pubmed: 18852878
Elife. 2016 Feb 16;5:e12735
pubmed: 26878752
PLoS Genet. 2014 Jan;10(1):e1004000
pubmed: 24465214
J Virol. 2010 Oct;84(19):9733-48
pubmed: 20660197
Virus Evol. 2017 Mar 02;3(1):vex003
pubmed: 28458914
Hepatology. 2015 Nov;62(5):1623-32
pubmed: 26095927
Top Antivir Med. 2017 Jul/Aug;25(3):103-109
pubmed: 28820725
Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6895-900
pubmed: 11371613
Viruses. 2021 Dec 29;14(1):
pubmed: 35062252
J Antimicrob Chemother. 2014 Jan;69(1):21-7
pubmed: 23963235
Nat Microbiol. 2019 Jul;4(7):1075-1087
pubmed: 31160826
Cell Mol Life Sci. 2016 Dec;73(23):4433-4448
pubmed: 27392606